Simon Fraser University
Engaging the World

The Proof of Concept Grant provides $100,000 over up to 3 years to support investigators with innovative, high-risk, high-yield hypotheses about dementia. The Alzheimer Society Research Program will pre-screen applications for the Proof of Concept Grant through a Letter of Intent (LOI) process. Successful LOI applicants will then be asked to submit a full application for peer review later in the summer.

This year's RFP seeks programs that focus on all novel approaches for Alzheimer’s disease and related dementias, with a particular emphasis on the areas of proteostasis and epigenetics. It provides up to $600,000 of funding support for two years.

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. NOTE: This funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones. We have dedicated our funding to several key areas: - Translational research to develop new drugs and build preclinical evidence - IND-enabling studies and early-stage clinical trials for novel and repurposed drugs - Development and validation of plasma, CSF, neuroimaging and digital biomarkers - Epidemiological studies and comparative effectiveness research

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. NOTE: This funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones. We have dedicated our funding to several key areas: - Translational research to develop new drugs and build preclinical evidence - IND-enabling studies and early-stage clinical trials for novel and repurposed drugs - Development and validation of plasma, CSF, neuroimaging and digital biomarkers - Epidemiological studies and comparative effectiveness research

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. NOTE: This funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones. We have dedicated our funding to several key areas: - Translational research to develop new drugs and build preclinical evidence - IND-enabling studies and early-stage clinical trials for novel and repurposed drugs - Development and validation of plasma, CSF, neuroimaging and digital biomarkers - Epidemiological studies and comparative effectiveness research

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) jointly announce that the Accelerating Drug Discovery for Frontotemporal Degeneration RFP is now accepting letters of intent. This RFP supports innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug development programs for frontotemporal dementia (FTD).

The Diagnostics Accelerator challenges the research community to develop cutting-edge biomarkers and explore novel diagnostic technologies that will aid in Alzheimer’s diagnosis and clinical trial design. Research funded to date focuses on various methods and targets including blood tests in various stages of development, as well as eye scans and digital tools.